Diagnostic Criteria for Refractory Ascites

Two Subtypes (IAC Classification)

A. Diuretic-Resistant Ascites

B. Diuretic-Intractable Ascites

Prior Treatment Requirements (must be met before labeling "refractory")

Operational Definitions

Key Points

• Compliance with sodium restriction must be confirmed before applying the label "refractory." Non-compliance is a common reason for apparent diuretic resistance. Spot urinary Na:K ratio or 24-hour urine sodium can help assess adherence.
• Patients who maintain urinary sodium excretion >30 mEq/day on diuretics may continue diuretics (even with refractory ascites) to prolong intervals between large-volume paracenteses (LVPs).
• Once refractory ascites is confirmed, diuretics should generally be stopped in non-responders to avoid adverse events.
• The classification was established by the International Ascites Club (Salerno et al.) and has been adopted by EASL and AASLD guidelines.

Management After Diagnosis

1. LVP + IV albumin (8 g per liter removed) - first-line
2. TIPS (covered stent preferred) - improves ascites control; survival benefit shown in recurrent ascites but not clearly in refractory ascites alone
3. Liver transplantation - definitive therapy; all eligible patients should be referred

Compensated vs. Decompensated Cirrhosis

Core Distinction

"The development of complications of variceal haemorrhage, ascites, encephalopathy, jaundice, or HCC characterizes decompensated cirrhosis. In compensated cirrhosis, these complications are absent."

• Sleisenger & Fordtran's GI and Liver Disease

The Four-Stage Clinical Model

• Stages 1-2 = Compensated cirrhosis
• Stages 3-4 = Decompensated cirrhosis
• Yamada's Textbook of Gastroenterology, 7th ed.

Clinical Features

Key Labs and Scores

Role of HVPG (Portal Pressure)

• Among patients with compensated cirrhosis followed >4 years, only 10% with HVPG <10 mmHg experienced decompensation, versus significantly more when HVPG ≥10 mmHg.
• HVPG and MELD are independent predictors of decompensation in compensated cirrhosis.
• Noninvasive surrogate: liver stiffness (transient elastography) >20 kPa = CSPH.
• Miller's Anesthesia, 10th ed.; Yamada's Textbook of Gastroenterology, 7th ed.

Prognosis

Practical Tips for Differentiation

1. Single decompensating event is enough - one episode of ascites, bleeding, or encephalopathy shifts the patient from compensated to decompensated.
2. Re-compensation is possible - with treatment of the underlying cause (e.g., viral hepatitis cure, alcohol abstinence), patients can revert to a compensated state, improving prognosis.
3. Infection is now recognized as a distinct stage in the natural history, associated with poor survival even after infection clearance.
4. ACLF (Acute-on-Chronic Liver Failure) represents an acute deterioration in decompensated patients with multi-organ failure and very high short-term mortality.

Serum-Ascites Albumin Gradient (SAAG)

Formula

• Both samples must be drawn on the same day (ideally simultaneously)
• It is a subtraction, not a ratio
• It does not change with diuresis - safe to calculate even in a patient on diuretics
• Accuracy: ~97% in identifying portal hypertension as the cause of ascites

Physiological Basis

Interpretation: The Cut-off

Step 1 - Categorize by SAAG

High SAAG (≥1.1 g/dL) - Portal Hypertensive Causes

Low SAAG (<1.1 g/dL) - Non-Portal Hypertensive (Peritoneal) Causes

Step 2 - For High SAAG: Sub-classify by Ascitic Fluid Total Protein

In cirrhosis, fibrosis deposits in sinusoids ("capillarization of the sinusoid") make them less permeable to macromolecules, resulting in low protein in the ascitic fluid - even though portal pressure is high.

Diagnostic Flowchart (Yamada's, Fig. 98.1)

Practical Pearls & Pitfalls

Additional Ascitic Fluid Tests by Indication

Summary Rule

SAAG ≥1.1  →  Portal hypertension
  + Ascitic protein <2.5  →  Cirrhosis (intrahepatic)
  + Ascitic protein ≥2.5  →  Cardiac / post-hepatic cause

SAAG <1.1  →  Peritoneal process
  (TB, malignancy, pancreatitis, nephrotic, etc.)

Best Site for Ascitic Paracentesis

Preferred Site: Left Lower Quadrant (LLQ)

3-5 cm superomedial (cranial and medial) to the anterior superior iliac spine (ASIS), lateral to the rectus sheath.

Why LLQ is Preferred Over Other Sites

Alternative Sites

Anatomical Structures to Avoid

• Inferior epigastric artery - runs within the rectus sheath bilaterally; stay lateral to the rectus muscle
• Surgical scars - adhesions underneath can tether bowel to the abdominal wall
• Abdominal wall collateral veins (caput medusae) - dilated in portal hypertension; visible and palpable
• Liver (right upper quadrant) and spleen (left upper quadrant)
• Urinary bladder - always empty the bladder (void or Foley catheter) before procedure
• Distended cecum (RLQ)

Positioning

• Supine with head of bed at 30-45° - standard
• Left lateral decubitus tilt - if using LLQ; allows fluid to pool toward the left flank
• A pillow under the flank on the opposite side helps shift fluid toward the puncture site
• For small fluid collections: lateral decubitus position with needle in the dependent (down) side

Needle Insertion Technique

Role of Ultrasound Guidance

Contraindications to Chosen Site

Spontaneous Bacterial Peritonitis (SBP): Diagnostic Criteria and Management

Definition

When to Suspect / Indications for Diagnostic Paracentesis

• Symptoms or signs of SBP: fever, abdominal pain/tenderness, ileus
• Unexplained hepatic encephalopathy
• Unexplained renal dysfunction
• Any hospitalized patient with cirrhosis and ascites, regardless of admission reason
• Upper GI bleeding in a cirrhotic patient
• New or worsening ascites

"Because SBP is often asymptomatic and frequently community acquired, diagnostic paracentesis should be performed when any patient with cirrhosis is admitted to the hospital." - Goldman-Cecil Medicine

Diagnostic Criteria

Primary Diagnostic Test: Ascitic Fluid PMN Count

Cultures are positive in only 40-60% of cases even with blood culture bottle inoculation. The diagnosis rests on the PMN count, not culture positivity.

SBP Variants

Distinguishing SBP from Secondary Bacterial Peritonitis

Management Algorithm

Treatment

1. Antibiotics

• Do NOT use aminoglycosides - nephrotoxic in cirrhosis
• Duration: 5-7 days (can be guided by PMN trend)
• Start empirically before culture results - do not delay

2. IV Albumin (Renal Protection)

"Albumin reduces the risk of renal failure and acute mortality" but does not reduce 3-month mortality in cirrhotic patients with infections other than SBP. - Goldman-Cecil Medicine

3. Monitoring Response

• Repeat diagnostic paracentesis at 48 hours
• Adequate response: PMN count decreased by ≥25% from baseline (some sources say ≥50%)
• If PMN fails to decrease: broaden antibiotic coverage, investigate secondary peritonitis with imaging

Prophylaxis

Secondary Prophylaxis (after an SBP episode) - MANDATORY

1-year SBP recurrence rate without prophylaxis is ~70%. Prophylaxis reduces this significantly.

Primary Prophylaxis

Prognosis

• In-hospital mortality: ~20-30%
• 2-year survival after SBP: ~30%
• All patients who survive SBP should be referred for liver transplant evaluation

Definitions: SIRS, Sepsis, and Septic Shock

Historical Context: Evolution of Definitions

1. SIRS - Systemic Inflammatory Response Syndrome

Definition

Criteria: ≥2 of the following 4

Causes of SIRS (non-infectious)

Why SIRS is no longer sufficient to define sepsis (Sepsis-3 rationale)

• SIRS is present in many hospitalized patients who never develop infection
• SIRS criteria fail to identify the key pathobiology: dysregulated host response causing organ dysfunction
• Both pro- and anti-inflammatory cascades are activated in sepsis - a purely inflammatory criterion misses this
• A SOFA increase of ≥2 has a 10% in-hospital mortality - SIRS alone does not carry this prognostic weight
• The term "severe sepsis" has been eliminated (all sepsis by Sepsis-3 involves organ dysfunction)

"The current use of 2 or more SIRS criteria to identify sepsis was unanimously considered by the task force to be unhelpful." - Sepsis-3 Task Force

2. Sepsis (Sepsis-3, 2016)

Definition

"Life-threatening organ dysfunction caused by a dysregulated host response to infection."

Operationalized as:

SOFA Score (Sequential Organ Failure Assessment)

qSOFA (Quick SOFA) - Bedside Screening Tool

3. Septic Shock (Sepsis-3)

Definition

Diagnostic Criteria (ALL three must be met):

Lactate >2 mmol/L must persist after volume resuscitation - this excludes simple hypovolemia.

Summary Comparison Table

Key Biomarkers in Sepsis

Surviving Sepsis Campaign 2021 - Key "1-Hour Bundle"

1. Measure lactate - re-measure if >2 mmol/L
2. Blood cultures before antibiotics
3. Broad-spectrum antibiotics within 1 hour
4. 30 mL/kg crystalloid IV for hypotension or lactate ≥4 mmol/L
5. Vasopressors (norepinephrine first-line) if hypotension persists - target MAP ≥65 mmHg

Role of Metronidazole in Hepatic Encephalopathy (HE)

Background: Why Antibiotics in HE?

Mechanism of Action of Metronidazole in HE

• Metronidazole is active against gram-negative anaerobes (e.g., Bacteroides spp.) that possess urease activity
• By reducing the burden of anaerobic bacteria, it decreases urease-mediated conversion of urea to ammonia in the gut
• This reduces both luminal and systemic ammonia levels
• It also has weak activity against Helicobacter pylori, another urease-producing organism implicated in HE

Place in Therapy

Evidence for Metronidazole

Key Studies

• Morgan et al. (1982, Gut) - Landmark study: metronidazole 200 mg QID × 7 days was as effective as neomycin in 18 patients with cirrhosis and HE. Both groups showed improvement in mental status (West Haven Criteria), reduction in asterixis, and lower arterial ammonia levels.
• Studies comparing metronidazole to rifaximin showed no significant difference in treatment duration (4.2 ± 2.1 days vs. 3.9 ± 1.7 days) or ammonia reduction - but rifaximin has a better safety profile.
• Mulholland & Greenfield: "Metronidazole for 7 days is as effective as neomycin."

2026 Cochrane Systematic Review (Most Recent Evidence)

Jeyaraj R, et al. Aminoglycosides, vancomycin, and metronidazole for people with cirrhosis and hepatic encephalopathy. Cochrane Database Syst Rev. 2026. [PMID: 41631546]

• 24 RCTs, 1405 participants; 3 trials specifically assessed metronidazole
• Certainty of evidence was low to very low for all comparisons, mainly due to:
  • High risk of bias in 22/24 trials
  • Small sample sizes
  • Significant heterogeneity
• Conclusion: Cannot draw firm conclusions about metronidazole's effects on mortality, HE outcomes, or adverse events compared to other agents due to insufficient evidence quality

AASLD/EASL 2014 Guideline Position

Recommendation 24: "Metronidazole is an alternative choice for treatment of overt hepatic encephalopathy (OHE)." (GRADE II-3, B, 2)

Dosing (When Used)

Adverse Effects Limiting Long-Term Use

Critical point: Metronidazole-induced encephalopathy can be clinically indistinguishable from hepatic encephalopathy itself - making it particularly dangerous in this patient population. Case reports exist of severe encephalopathy in end-stage liver disease patients on metronidazole. The drug accumulates in liver failure due to reduced hepatic clearance.

Why Rifaximin Replaced Metronidazole as the Preferred Antibiotic

Summary

• Metronidazole acts by reducing urease-producing anaerobic gut bacteria and thus lowering ammonia production
• It is as effective as neomycin short-term, but not superior to rifaximin
• It is classified as an alternative/third-line agent in both AASLD/EASL guidelines
• Its use is restricted to short courses (≤7-14 days) due to risk of peripheral neuropathy and encephalopathy - ironic and dangerous in a population already prone to encephalopathy
• In liver failure, metronidazole accumulates due to impaired hepatic metabolism, increasing toxicity risk
• Rifaximin + lactulose remain the standard of care; metronidazole is reserved for situations where rifaximin is unavailable or unaffordable